Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × larotrectinib × 1 year × Clear all

Phase

Phase 2 6 Phase 4 2 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 192 Nivolumab 108 Cyclophosphamide 105 Carboplatin 88 venetoclax 69 Gemcitabine 68 Bevacizumab 68 fludarabine 63 Dexamethasone 62 Specimen Handling 60 Injections 59 Magnetic Resonance Spectroscopy 57 Paclitaxel 56 atezolizumab 54 Biopsy 54 Cisplatin 47 Ipilimumab 46 Temozolomide 42 Rituximab 42 Pemetrexed 41 Docetaxel 39 Azacitidine 39 Oxaliplatin 38 Radiotherapy 37 Lenalidomide 35 Fluorouracil 35 Cetuximab 35 Prednisone 34 Irinotecan 33 Cytarabine 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡